Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study

Fig. 2

Investigators-assessed survival outcomes. a Overall survival of patients (as-treated population, N = 38). b Progression-free survival of patients (as-treated population, N = 38). c Overall survival of patients with CR or PR versus SD or PD (intention-to-treat population, N = 37). d Progression-free survival of patients with CR or PR versus SD or PD (intention-to-treat population, N = 37)

Back to article page